Meera R Chappidi1, Max Kates2, Michael H Johnson2, Noah M Hahn3, Trinity J Bivalacqua2, Phillip M Pierorazio2. 1. The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD. Electronic address: mchappi1@jhmi.edu. 2. The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD. 3. The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD.
Abstract
PURPOSE: The purpose of the study was to characterize the contemporary trends in lymphadenectomy for the treatment of upper tract urothelial carcinoma in a population-based cohort and to determine if number of lymph nodes removed and tumor location are predictors of cancer-specific survival in patients undergoing nephroureterectomy. MATERIALS AND METHODS: Individuals with upper tract urothelial carcinoma undergoing nephroureterectomy in the Surveillance, Epidemiology, and End Results program from 2004 to 2012 were identified. Linear regression was used to assess trends in lymphadenectomy. Patients were stratified based on nodal status, quartiles of nodes removed, and tumor location. Kaplan-Meier analysis, log-rank tests, and Cox proportional hazards models were used to compare cancer-specific survival and overall survival among groups. RESULTS: In the cohort, 25% (721/2,862) of all patients and 27% (566/2,079) of grade 3/4 patients underwent lymphadenectomy. The percentage of patients undergoing lymphadenectomy increased from 20% (60/295) in 2004 to 33% (106/320) in 2012 (P = 0.02). Patients with the highest quartile of lymph nodes removed had improved the 5-year cancer-specific survival of 78% (95% CI: 69%-85%) compared to the second quartile (60%; 95% CI: 51%-67%; P = 0.003) and the third quartile (60%; 95% CI: 51%-68%; P = 0.002) of nodes removed. This trend held for node-negative and node-positive patients. In multivariable modeling, a lower number of lymph nodes dissected (hazard ratio = 0.94, 95% CI: 0.91-0.98) and ureteral tumors (hazard ratio = 1.29, 95% CI: 1.07-1.56) were predictors of worse cancer-specific survival. CONCLUSIONS: In patients with upper tract urothelial carcinoma undergoing nephroureterectomy, rates of lymphadenectomy have increased from 2004 to 2012 in the United States. In this contemporary cohort, an increase in the number of nodes removed and renal pelvis tumors are associated with improved cancer-specific survival, which highlights the importance of intentional lymph node dissection with adequate lymph node yield in these patients. Copyright Â
PURPOSE: The purpose of the study was to characterize the contemporary trends in lymphadenectomy for the treatment of upper tract urothelial carcinoma in a population-based cohort and to determine if number of lymph nodes removed and tumor location are predictors of cancer-specific survival in patients undergoing nephroureterectomy. MATERIALS AND METHODS: Individuals with upper tract urothelial carcinoma undergoing nephroureterectomy in the Surveillance, Epidemiology, and End Results program from 2004 to 2012 were identified. Linear regression was used to assess trends in lymphadenectomy. Patients were stratified based on nodal status, quartiles of nodes removed, and tumor location. Kaplan-Meier analysis, log-rank tests, and Cox proportional hazards models were used to compare cancer-specific survival and overall survival among groups. RESULTS: In the cohort, 25% (721/2,862) of all patients and 27% (566/2,079) of grade 3/4 patients underwent lymphadenectomy. The percentage of patients undergoing lymphadenectomy increased from 20% (60/295) in 2004 to 33% (106/320) in 2012 (P = 0.02). Patients with the highest quartile of lymph nodes removed had improved the 5-year cancer-specific survival of 78% (95% CI: 69%-85%) compared to the second quartile (60%; 95% CI: 51%-67%; P = 0.003) and the third quartile (60%; 95% CI: 51%-68%; P = 0.002) of nodes removed. This trend held for node-negative and node-positive patients. In multivariable modeling, a lower number of lymph nodes dissected (hazard ratio = 0.94, 95% CI: 0.91-0.98) and ureteral tumors (hazard ratio = 1.29, 95% CI: 1.07-1.56) were predictors of worse cancer-specific survival. CONCLUSIONS: In patients with upper tract urothelial carcinoma undergoing nephroureterectomy, rates of lymphadenectomy have increased from 2004 to 2012 in the United States. In this contemporary cohort, an increase in the number of nodes removed and renal pelvis tumors are associated with improved cancer-specific survival, which highlights the importance of intentional lymph node dissection with adequate lymph node yield in these patients. Copyright Â
Authors: Giovanni Lughezzani; Maximilian Burger; Vitaly Margulis; Surena F Matin; Giacomo Novara; Morgan Roupret; Shahrokh F Shariat; Christopher G Wood; Richard Zigeuner Journal: Eur Urol Date: 2012-02-23 Impact factor: 20.096
Authors: Firas Abdollah; Maxine Sun; Jan Schmitges; Orchidee Djahangirian; Zhe Tian; Claudio Jeldres; Paul Perrotte; Shahrokh F Shariat; Francesco Montorsi; Pierre I Karakiewicz Journal: BJU Int Date: 2011-08-24 Impact factor: 5.588
Authors: Maximilian Burger; Shahrokh F Shariat; Hans-Martin Fritsche; Juan Ignacio Martinez-Salamanca; Kazumasa Matsumoto; Thomas F Chromecki; Vincenzo Ficarra; Wassim Kassouf; Christian Seitz; Armin Pycha; Stefan Tritschler; Thomas J Walton; Giacomo Novara Journal: World J Urol Date: 2011-06-01 Impact factor: 4.226
Authors: Michael Rink; Behfar Ehdaie; Eugene K Cha; David A Green; Pierre I Karakiewicz; Marko Babjuk; Vitaly Margulis; Jay D Raman; Robert S Svatek; Harun Fajkovic; Richard K Lee; Giacomo Novara; Jens Hansen; Siamak Daneshmand; Yair Lotan; Wassim Kassouf; Hans-Martin Fritsche; Armin Pycha; Margit Fisch; Douglas S Scherr; Shahrokh F Shariat Journal: Eur Urol Date: 2012-02-15 Impact factor: 20.096
Authors: C Valignat; J M Marechal; O Rouviere; A Gelet; X Martin; C Castagnola; D Lyonnet; J M Dubernard Journal: Prog Urol Date: 1997-04 Impact factor: 0.915
Authors: Giovanni Lughezzani; Maxine Sun; Paul Perrotte; Shahrokh F Shariat; Claudio Jeldres; Lars Budäus; Mathieu Latour; Hugues Widmer; Alain Duclos; Francois Bénard; Michael McCormack; Francesco Montorsi; Pierre I Karakiewicz Journal: Urology Date: 2009-12-04 Impact factor: 2.649
Authors: Ilker Tinay; Francisco Gelpi-Hammerschmidt; Jeffrey J Leow; Christopher B Allard; Dayron Rodriguez; Ye Wang; Benjamin I Chung; Steven L Chang Journal: BJU Int Date: 2015-12-23 Impact factor: 5.588
Authors: Giovanni Lughezzani; Claudio Jeldres; Hendrik Isbarn; Shahrokh F Shariat; Maxine Sun; Daniel Pharand; Hugues Widmer; Philippe Arjane; Markus Graefen; Francesco Montorsi; Paul Perrotte; Pierre I Karakiewicz Journal: Urology Date: 2009-10-28 Impact factor: 2.649
Authors: Marco Moschini; Beat Foerster; Mohammad Abufaraj; Francesco Soria; Thomas Seisen; Morgan Roupret; Pierre Colin; Alexandre De la Taille; Benoit Peyronnet; Karim Bensalah; Roman Herout; Manfred Peter Wirth; Vladimir Novotny; Piotr Chlosta; Marco Bandini; Francesco Montorsi; Giuseppe Simone; Michele Gallucci; Giuseppe Romeo; Kazumasa Matsumoto; Pierre Karakiewicz; Alberto Briganti; Shahrokh F Shariat Journal: World J Urol Date: 2017-02-28 Impact factor: 4.226
Authors: Niv Milbar; Max Kates; Meera R Chappidi; Filippo Pederzoli; Takahiro Yoshida; Alexander Sankin; Phillip M Pierorazio; Mark P Schoenberg; Trinity J Bivalacqua Journal: Bladder Cancer Date: 2017-10-27